# Unregulated Substance Abuse and Systemic Inflammation Markers: A Review. > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/inflammatory-biomarkers-unregulated-substance-use-review/ > **Published:** 2026-03-26T12:08:37-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:37:36-04:00 > **Clinical Summary:** This review explores inflammatory biomarkers unregulated substance use and their clinical relevance in assessing systemic inflammation risks. --- CED Clinical Relevance  #55Monitored Relevance  Early-stage or contextual signal requiring further evidence before action. 🔬 Evidence Watch  |  CED Clinic Inflammation[Substance Use](https://cedclinic.com/stroke-risk-assessment-substance-use/)BiomarkersPolysubstanceReview Journal Healthcare (Basel, Switzerland) Study Type [Clinical Study](https://cedclinic.com/cannabis-hyperemesis-syndrome-psychiatric-risk/) Population Human participants Why This Matters This review examines the relationship between unregulated [substance use](https://cedclinic.com/stroke-risk-assessment-substance-use/) and inflammatory biomarkers, which is clinically relevant given that many patients using cannabis therapeutically may also use other unregulated substances. Understanding these interactions helps clinicians assess overall health risks and monitor appropriate biomarkers. Clinical Summary This review analyzed existing literature on how unregulated substances affect systemic inflammation markers in human participants. The study synthesized evidence showing that various unregulated substances can elevate inflammatory biomarkers like C-reactive protein, interleukins, and TNF-alpha, though the specific mechanisms and clinical significance vary by substance class. The review highlights gaps in current research methodology and the need for more standardized approaches to studying these relationships. A key limitation is the heterogeneity of substances studied and inconsistent measurement protocols across different research groups. Dr. Caplan’s Take “This review reinforces what I see clinically – patients rarely use substances in isolation, and we need to consider the full spectrum of exposures when evaluating inflammatory conditions. However, the lack of cannabis-specific data limits its immediate applicability to my [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) practice.” Clinical Perspective 🧠 Clinicians should consider baseline inflammatory marker testing in patients with polysubstance use patterns, particularly when treating chronic inflammatory conditions. This information supports the importance of comprehensive substance use histories and may inform monitoring protocols, though more cannabis-specific research is needed to guide therapeutic decision-making. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Unregulated%20Substance%20Abuse%20and%20Systemic%20Inflammation%20Markers%3A%20A%20Review.%20%40drcaplan&url=https%3A//pubmed.ncbi.nlm.nih.gov/41595368/)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//pubmed.ncbi.nlm.nih.gov/41595368/)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Unregulated%20Substance%20Abuse%20and%20Systemic%20Inflammation%20Markers%3A%20A%20Review.%20--%20via%20%40drcaplan.bsky.social%20https%3A//pubmed.ncbi.nlm.nih.gov/41595368/)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://pubmed.ncbi.nlm.nih.gov/41595368/](https://pubmed.ncbi.nlm.nih.gov/41595368/) Table of Contents - [FAQ](#FAQ)[What inflammatory markers should I monitor in patients with unregulated substance use?](#What_inflammatory_markers_should_I_monitor_in_patients_with_unregulated_substance_use) - [How does polysubstance use affect inflammatory responses compared to single substance use?](#How_does_polysubstance_use_affect_inflammatory_responses_compared_to_single_substance_use) - [Should I routinely screen for inflammation in all substance-using patients?](#Should_I_routinely_screen_for_inflammation_in_all_substance-using_patients) - [Can elevated inflammatory markers predict treatment outcomes in substance use disorders?](#Can_elevated_inflammatory_markers_predict_treatment_outcomes_in_substance_use_disorders) - [How should I interpret inflammatory marker results in the context of substance use?](#How_should_I_interpret_inflammatory_marker_results_in_the_context_of_substance_use) - [Related](#Related) ## FAQ #### What inflammatory markers should I monitor in patients with unregulated substance use? Key inflammatory biomarkers to consider include C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α). These markers can help assess systemic inflammation burden and guide treatment decisions, though current evidence requires further validation before routine clinical implementation. #### How does polysubstance use affect inflammatory responses compared to single substance use? Polysubstance use typically produces more complex and pronounced inflammatory responses than single substance use. The interaction between multiple substances can amplify systemic inflammation, potentially leading to greater health complications and requiring more comprehensive monitoring approaches. #### Should I routinely screen for inflammation in all substance-using patients? Currently, routine inflammatory screening is not standard practice as this remains an early-stage research area. Consider inflammatory marker testing in patients with concurrent medical conditions, unexplained symptoms, or those at high risk for inflammatory complications from their substance use patterns. #### Can elevated inflammatory markers predict treatment outcomes in substance use disorders? Emerging evidence suggests inflammatory biomarkers may have predictive value for treatment response and relapse risk. However, this application requires further research validation before being incorporated into standard clinical decision-making protocols. #### How should I interpret inflammatory marker results in the context of substance use? Interpret results cautiously, considering other factors that influence inflammation such as infections, chronic diseases, and medication effects. Elevated markers may indicate increased health risks but should be evaluated within the broader [clinical context](https://cedclinic.com/cannabis-hyperemesis-syndrome-treatment-insights-2026/) rather than as standalone diagnostic tools. {“@context”: “https://schema.org”, “@type”: “ScholarlyArticle”, “headline”: “Unregulated Substance Abuse and Systemic Inflammation Markers: A Review.”, “url”: “https://pubmed.ncbi.nlm.nih.gov/41595368/”, “about”: “healthcare basel switzerland [clinical study](https://cedclinic.com/cannabis-hyperemesis-syndrome-psychiatric-risk/) unregulated”, “isPartOf”: “Healthcare (Basel, Switzerland)”} [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Substance Use and Suicide Attempts in Adolescents: A Comparative Analysis of Clinical and Psychosocial Risk Factors.](https://cedclinic.com/adolescent-substance-use-suicide-risk-analysis/) Explore the clinical and psychosocial risk factors linking substance use and suicide attempts in adolescents, providing insights into prevention strategies. [Read More](https://cedclinic.com/adolescent-substance-use-suicide-risk-analysis/) [Cannabinoid Therapies in Less-Common Disorders: Clinical Evidence and Formulation Strategies.](https://cedclinic.com/cannabinoid-therapies-rare-diseases-evidence-formulation/) Review [clinical evidence](https://cedclinic.com/academic-partnerships-cannabis-research/) and formulation strategies for cannabinoid therapies targeting less-common disorders, highlighting therapeutic potentials. [Explore Now](https://cedclinic.com/cannabinoid-therapies-rare-diseases-evidence-formulation/) [Lifestyle and Behavioral Enhancements of Sleep: A Review.](https://cedclinic.com/sleep-hygiene-cbt-i-lifestyle-enhancements/) This review discusses lifestyle and behavioral approaches to improve sleep quality, relevant for patients with inflammatory and substance use conditions. [Learn More](https://cedclinic.com/sleep-hygiene-cbt-i-lifestyle-enhancements/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).